Decoding spatial mTOR signalling reveals distinct roles in the tumour microenvironment.

Razan Zuhair¹, Mark Eastwood², Megan Bradbury³, Amy Cross³, Joanna Hester³, Fadi Issa³, Fiona Ginty⁴, Heba Z Sailem^5,6

¹School of Cancer and Pharmaceutical Sciences, Stamford St., Franklin Wilkins Building, King's College London, London, UK.

²Tissue Image Analytics Center, University of Warwick, Coventry, UK.

³Nuffield Department of Surgical Sciences, Level 6, John Radcliffe Hospital, University of Oxford, Oxford, UK.

⁴GE HealthCare Technology and Innovation Center, Niskayuna, NY, USA.

⁵School of Cancer and Pharmaceutical Sciences, Stamford St., Franklin Wilkins Building, King's College London, London, UK. heba.sailem@kcl.ac.uk.

⁶Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Oxford, UK. heba.sailem@kcl.ac.uk.

PubMed DOI

Abstract

The tumour microenvironment comprises a variety of cell types that interact with malignant cells, influencing both cancer progression and the patient response to therapy. Given the intricate interactions among these components, assessing how signalling pathways contribute to cancer progression by acting on different components of the TME is particularly complex. Multiplexed imaging allows simultan…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.